Cardiovascular Research

Papers
(The H4-Index of Cardiovascular Research is 48. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options979
Global burden of heart failure: a comprehensive and updated review of epidemiology514
Cardiac fibrosis409
Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science311
Hypertension, the renin–angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19246
Regional and global contributions of air pollution to risk of death from COVID-19209
Higher mortality of COVID-19 in males: sex differences in immune response and cardiovascular comorbidities193
Vascular smooth muscle cells in atherosclerosis: time for a re-assessment171
SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes170
Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation159
Endothelial function in cardiovascular medicine: a consensus paper of the European Society of Cardiology Working Groups on Atherosclerosis and Vascular Biology, Aorta and Peripheral Vascular Diseases,159
Angiogenesis after acute myocardial infarction144
The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction101
Gut microbiota dysbiosis promotes age-related atrial fibrillation by lipopolysaccharide and glucose-induced activation of NLRP3-inflammasome100
Metabolic inflammation in heart failure with preserved ejection fraction99
Neutrophil extracellular traps: from physiology to pathology95
Single-cell RNA sequencing reveals the cellular heterogeneity of aneurysmal infrarenal abdominal aorta94
Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute Card91
Evidence of SARS-CoV-2 mRNA in endomyocardial biopsies of patients with clinically suspected myocarditis tested negative for COVID-19 in nasopharyngeal swab89
Senescence mechanisms and targets in the heart87
NLRP3 inflammasome as a key driver of vascular disease81
Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart76
Obesity, kidney dysfunction, and inflammation: interactions in hypertension76
Environmental risk factors and cardiovascular diseases: a comprehensive expert review76
The role of CD36 in cardiovascular disease72
Towards standardization of echocardiography for the evaluation of left ventricular function in adult rodents: a position paper of the ESC Working Group on Myocardial Function72
Single-cell analysis of SARS-CoV-2 receptor ACE2 and spike protein priming expression of proteases in the human heart69
Optimizing indices of atrial fibrillation susceptibility and burden to evaluate atrial fibrillation severity, risk and outcomes66
NLRP3 inflammasome is a key driver of obesity-induced atrial arrhythmias64
mRNA modifications in cardiovascular biology and disease: with a focus on m6A modification63
COVID-19 as a cardiovascular disease: the potential role of chronic endothelial dysfunction63
Pathophysiology of atrial fibrillation and chronic kidney disease61
Inflammation and cardiovascular diseases: lessons from seminal clinical trials57
Targeting mitochondrial fission as a potential therapeutic for abdominal aortic aneurysm56
Mechanism of succinate efflux upon reperfusion of the ischaemic heart56
Loss of Yap/Taz in cardiac fibroblasts attenuates adverse remodelling and improves cardiac function55
The key contribution of platelet and vascular arachidonic acid metabolism to the pathophysiology of atherothrombosis54
Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications53
Long COVID and the cardiovascular system—elucidating causes and cellular mechanisms in order to develop targeted diagnostic and therapeutic strategies: a joint Scientific Statement of the ESC Working 53
Emerging views of statin pleiotropy and cholesterol lowering53
Ketones can become the major fuel source for the heart but do not increase cardiac efficiency52
Organ-on-a-chip technology: a novel approach to investigate cardiovascular diseases52
Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-151
Plasma levels of trimethylamine-N-oxide can be increased with ‘healthy’ and ‘unhealthy’ diets and do not correlate with the extent of atherosclerosis but with plaque instability51
Improving translational research in sex-specific effects of comorbidities and risk factors in ischaemic heart disease and cardioprotection: position paper and recommendations of the ESC Working Group 51
Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets50
Critical examination of mechanisms underlying the reduction in heart failure events with SGLT2 inhibitors: identification of a molecular link between their actions to stimulate erythrocytosis and to a50
Association of cardiometabolic microRNAs with COVID-19 severity and mortality49
Physiological and pathological roles of protein kinase A in the heart48
0.28660106658936